Three tumours contained mutations in ERBB2/RAS/RAF/MEK pathway members or regulators: an ARAF mutation in combination with a NCK1 mutation, a PAK1 mutation in combination with a NF1 mutation, and an ERBB2 mutation in combination with a TSC1 mutation. Here, ERBB2 is linked to neoplasm.